Athenex, Inc. 與貸方達成協議，推動快速銷售進程
May 15, 2023 11:33 ET
|
Athenex, Inc.
為更好地推進事務發展，公司自願申請第 11 章破產程序 公司擁有足夠的資源支援 Athenex Pharma Solutions 的營運，並在此進程期間，完成 APD 客戶訂單 紐約布法羅, May 15, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:...
Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process
May 14, 2023 11:15 ET
|
Athenex, Inc.
To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process ...
Athenex 發布 2022 年第四季度及全年財務業績及業務更新
March 22, 2023 14:30 ET
|
Athenex, Inc.
探索一系列戰略備選方案 2022 年第四季度來自持續經營的產品銷售收入同比增長 +27%，2022 年全年增長 +33% Athenex 於 2022年第四季度應佔淨虧損為 3,420 萬美元，或每股經攤薄股份 4.28 美元，而上年同期為 1.044 億美元，或每股經攤薄股份 19.08 美元 至年底，現金、現金等價物和受限現金餘額為 3,560 萬美元 KUR-502 CAR-NKT...
Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update
March 20, 2023 08:00 ET
|
Athenex, Inc.
Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was...
Athenex 宣佈反向股票分割
February 14, 2023 11:30 ET
|
Athenex, Inc.
紐約州布法羅市, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ：ATNX)，一家致力於癌症和相關疾病治療新療法的發現、開發和商業化的全球生物製藥公司今天宣佈，將於 2023 年 2 月 15 日東部時間上午 12:01 對其發行的普通股進行 1:20 的反向股票分割。從明天（2023 年 2 月 15...
Athenex Announces a Reverse Stock Split
February 14, 2023 08:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies...
Athenex 宣佈 MHRA 關於口服紫杉醇的決定
January 03, 2023 13:28 ET
|
Athenex, Inc.
MHRA 僅以化學成分、生產和控制 (CMC) 問題為由拒絕了口服紫杉醇治療轉移性乳腺癌的申請Athenex 計劃要求一個獨立小組對 MHRA 的決定進行審查 MHRA 的申請補充了來自 iSPY 2 研究的安全性數據，未表現出重大臨床療效或安全性問題 紐約州布法羅, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:...
Athenex Announces MHRA Decision on Oral Paclitaxel
January 03, 2023 08:00 ET
|
Athenex, Inc.
MHRA denies Oral Paclitaxel for metastatic breast cancer based solely on chemistry, manufacturing and control (CMC) issuesAthenex plans to request a review of the MHRA decision by an independent panel...
Athenex 宣布 Quantum Leap Healthcare Collaborative 報告口服紫杉醇聯合 PD-1 和卡鉑在乳腺癌新輔助治療中的 I-SPY2 試驗結果顯著
December 20, 2022 12:14 ET
|
Athenex, Inc.
紐約水牛城, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX)，一家致力於癌症及相關疾病新療法的發現、開發和商業化的全球性生物製藥公司今日宣布，其在 Quantum Leap Healthcare Collaborative 的合作者報告稱公司的口服紫杉醇聯合 encequidar 與 PD-1...
Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer
December 20, 2022 08:15 ET
|
Athenex, Inc.
BUFFALO, N.Y., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies...